Maravai LifeSciences Reports Q2 2026 Financial Results

What Happened

• On August 6, 2026 Maravai LifeSciences Holdings, Inc. (MRVI) filed a Form 8-K (Item 2.02) to announce its second-quarter 2026 results of operations and financial condition. The company issued a press release with the results, which is furnished as Exhibit 99.1 to the filing. The report was signed by Chief Financial Officer Rajesh Asarpota.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02).
• Event: Press release announcing Q2 2026 financial results (Exhibit 99.1 furnished).
• Exhibit note: Exhibit 99.1 is furnished (not “filed”) and therefore is not subject to Section 18 liability or automatically incorporated by reference.
• Administrative: Interactive XBRL cover page included (Exhibit 104); signature by CFO Rajesh Asarpota.

Why It Matters

• The 8-K makes Maravai’s Q2 2026 earnings and related commentary available to investors. While the filing itself furnishes the press release rather than embedding financial tables in the 8-K text, the exhibit should contain the company’s reported earnings, revenue, and any management commentary or guidance. Investors should review Exhibit 99.1 (the press release) for the detailed quarterly results and any implications for revenue, earnings, or near-term outlook.